News

PipelineReview.com9h
Imugene Announces Outstanding Response Rates from the Phase 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCL
SYDNEY, Australia I July 14, 2025 I Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, is pleased to ...
PipelineReview.com5h
TSLP (thymic stromal lymphoprotein) is a clinically and commercially validated inflammatory target attracting numerous competitors
TSLP inhibitor Tezspire clinically has validated Thymic Stromal LymphoPoietin (TSLP) as a valid target for treatment of inflammatory diseases by its approval in late 2021 in the US and in 2022 in ...
PipelineReview.com9h
Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1
OSAKA, Japan and CAMBRIDGE, MA, USA I July 14, 2025 I Takeda (TSE:4502/NYSE:TAK) today announced that all primary and secondary endpoints were met in two ...
PipelineReview.com9h
Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
Complete Response Letter (CRL) cited specific chemistry, manufacturing and controls (CMC) related observations that are resolvable ...
PipelineReview.com9h
Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo ...